50961-54-1

Basic information

• Product Name: 4-(4-NITROPHENOXY)BENZALDEHYDE 97
• Synonyms: 4-(4-NITROPHENOXY)BENZALDEHYDE 97
• CAS NO: 50961-54-1
• Molecular Formula: C₁₃H₉NO₄
• Molecular Weight: 243.217
• Product Categories: Aldehydes;C10 to C21;Carbonyl Compounds;Building Blocks;C13-C60;Carbonyl Compounds;Chemical Synthesis;Organic Building Blocks
• Mol File: 50961-54-1.mol
• Article Data: 20

Chemical Properties

• Melting Point: 106-110 °C
• Boiling Point: 386.1°C at 760 mmHg
• Flash Point: 175°C
• Appearance: /
• Density: 1.325g/cm³
• Vapor Pressure: 3.63E-06mmHg at 25°C
• Refractive Index: 1.638
• CAS DataBase Reference: 4-(4-NITROPHENOXY)BENZALDEHYDE 97(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-NITROPHENOXY)BENZALDEHYDE 97(50961-54-1)
• EPA Substance Registry System: 4-(4-NITROPHENOXY)BENZALDEHYDE 97(50961-54-1)

Safety Data

• Hazard Codes: Xi,N
• Statements: 41-43-50/53
• Safety Statements: 26-36/39-60-61
• RIDADR: UN 3077 9/PG 3
• WGK Germany: 3
• Hazardous Substances Data: 50961-54-1(Hazardous Substances Data)

Usage

General Description

4-(4-Nitrophenoxy)benzaldehyde 97 is an organic chemical compound with the molecular formula C13H9NO4. It is a pale yellow solid with a molecular weight of 247.22 g/mol. 4-(4-NITROPHENOXY)BENZALDEHYDE 97 is commonly used in organic synthesis and as an intermediate in the production of various pharmaceuticals, dyes, and other organic compounds. It is also used in research and development processes in the chemical industry. 4-(4-Nitrophenoxy)benzaldehyde 97 is known for its strong, sweet, floral-like odor and should be handled with care due to its potential to cause skin and eye irritation.

InChI:InChI=1/C13H9NO4/c15-9-10-1-5-12(6-2-10)18-13-7-3-11(4-8-13)14(16)17/h1-9H

Upstream product

• 67-36-7 4-phenoxy benzaldehyde 
• 20850-44-6 (4-chloromethyl-phenyl)-(4-nitro-phenyl)-ether 
• 100-00-5 4-chlorobenzonitrile 
• 100-02-7 4-nitro-phenol 
• 459-57-4 4-fluorobenzaldehyde 
• 123-08-0 4-hydroxy-benzaldehyde 
• 101-84-8 diphenylether 
• 350-46-9 4-Fluoronitrobenzene 
• 586-78-7 para-nitrophenyl bromide 
• 1122-91-4 4-bromo-benzaldehyde 

Downstream Products

• 16309-45-8 4-(4-nitrophenoxy)benzoic acid 
• 92498-24-3 3-<4-(4-Nitro-phenoxy)-phenyl>-acrylsaeure 
• 516481-35-9 2-[4-(4-Nitro-phenoxy)-phenyl]-1H-benzoimidazole-5-carboxylic Acid 
• 516481-81-5 2-[4-(4-aminophenoxy)phenyl]-1H-benzimidazole-5-carboxylic acid amide 
• 516481-08-6 2-[4-(4-nitro-phenoxy)-phenyl]-1H-benzoimidazole-5-carboxylic acid amide 
• 92553-01-0 3-<4-(4-Amino-phenoxy)-phenyl>-acrylsaeure 
• 50961-38-1 N,N'-bis[4-(4'-nitrophenoxy)benzal]-1,6-hexanediamine 
• 51055-70-0 N,N'-bis[4-(4'-nitrophenoxy)benzal]-1,8-octanediamine 
• 50961-57-4 bis{3-[4-(4'-nitrophenoxy)-benzalamino]propyl}amine 
• 50961-52-9 1,4-bis{2-[4-(4'-nitrophenoxy)benzalamino]ethyl}-2,3,5,6-tetramethylbenzene 
• 50961-56-3 1,2'-dimethylbis{2-[4(4'-nitrophenoxy)benzalamino]ethyl}amine 
• 1160168-48-8 2-cyanomethylene-5-[4-(4-nitrophenoxy)benzylidene]-4-thiazolinone 

Relevant articles and documents

Synthesis and cytotoxicity of novel chromenone derivatives bearing 4-nitrophenoxy phenyl acryloyl moiety

This work describes synthesis of novel chromenone derivatives bearing 4-nitrophenoxy phenyl acryloyl moiety through the reaction of 4-(4-nitrophenoxy)benzaldehydes and 3-acetyl-2H-chromen-2-ones in refluxing toluene. Cytotoxicity of all compounds was eval

Computational study and synthesis of a new class of anticonvulsants with 6 Hz psychomotor seizure test activity: 2-(1,3-benzodioxol-5-yloxy)-N'-[substituted]-acetohydrazides

Background: About 50 million epileptic cases worldwide and 12 million in India are re-ported. Currently, available drugs yield adequate control of seizure in 60-70% of patients and show many toxic effects. These actualities provoked the search for novel, more efficacious and safer anti-convulsants. Objective: The concatenation of 2-(1,3-benzodioxol-5-yloxy)-N'-[substituted]-acetohydrazides SA 1-10 was designed by molecular hybridization, optimized by computational study and synthesized with the objective of obtaining a prototype of potent anticonvulsant molecules especially active against partial seizures. Methods: Computational study was performed to calculate the pharmacophoric design, projection of the pharmacokinetic parameters and docking scores of the titled compounds with molecular targets of epilepsy. The anticonvulsant activity was ascertained by 6 Hz psychomotor seizure test. Minimal motor impairment showing neurotoxicity was assessed using the Rotarod test. Results: Titled compounds possessed the indispensable elements of pharmacophore and displayed good binding affinity with molecular targets of epilepsy, such as GABA (A) alpha-1 & delta receptor, glutamate receptor, Na+/H+ exchanger and GABA-aminotransferase in docking studies. The most potent compound of the concatenation was 2-(1,3-benzodioxol-5-yloxy)-N'-[4-(4-chlorophenoxy)benzylidene]-acetohydrazide SA 4, showing 100% protection at four different time points with ED50 value 146.8 mg/kg at a TPE of 1 h in mice. Conclusion: The protection shown in 6 Hz test is implicated as the compound's ability to control partial seizures. Thus, the titled compounds can be considered as potential prototype candidates for antiepileptic therapy against partial seizures.

Synthesis and evaluation of new diaryl ether and quinoline hybrids as potential antiplasmodial and antimicrobial agents

Synthesis and bioevaluation of new diaryl ether hybridized quinoline derivatives as antiplasmodial, antibacterial and antifungal agents is reported. It was encouraging to discover that several compounds displayed 2-3 folds better efficacy than chloroquine in chloroquine-resistant K1 strain of Plasmodium falciparum. Further, a few members of the library displayed good antibacterial efficacy against gram positive strains of bacteria but none of the compounds displayed any significant antifungal activity.